Zhou Zhuoming, Liang Mengya, Huang Suiqing, Wu Zhongkai
Department of Cardiac Surgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
NHC Key Laboratory of Assisted Circulation, Sun Yat-sen University, Guangzhou, China.
J Thorac Dis. 2020 Sep;12(9):4742-4753. doi: 10.21037/jtd-20-1407.
Valve-sparing aortic root replacement (VSARR), which includes reimplantation and remodeling techniques, has been developed as an important treatment for aortic root aneurysms. We aimed to evaluate the outcomes of reimplantation versus remodeling techniques in valve-sparing surgery for aortic root aneurysms.
A systematic review and meta-analysis was performed by searching PubMed, Embase and the Cochrane Library until November 2019. Fourteen retrospective cohort studies comparing reimplantation with remodeling techniques for aortic root aneurysms were included and contained at least one of the following outcomes: early mortality, late mortality, aortic valve-related reoperation, and postoperative moderate to severe aortic regurgitation (AR).
The outcomes of 1,672 patients (1,011 underwent reimplantation surgery, and 661 underwent remodeling) were analyzed. Compared with remodeling, the reimplantation technique was associated with a significantly lower risk of late mortality (RR =0.34; 95% CI, 0.17-0.71; P=0.004; I=37%) and reoperation (RR =0.31; 95% CI, 0.12-0.76; P=0.01; I=55%). There was no significant difference in early mortality (RR =0.69; 95% CI, 0.31-1.53; P=0.36; I=0%), postoperative moderate to severe AR (RR =0.64; 95% CI, 0.31-1.32; P=0.22; I=36%) or postoperative stroke (RR =1.26; 95% CI, 0.58-2.75; P=0.56; I=0%) between the two groups. No evidence of publication bias was detected.
The current meta-analysis indicate that patients who undergo reimplantation procedures have a significantly lower risk of late mortality and reoperation than those who undergo remodeling procedures. Early mortality, postoperative moderate to severe AR and stroke were comparable between the two techniques.
保留瓣膜的主动脉根部置换术(VSARR),包括再植入和重塑技术,已发展成为治疗主动脉根部瘤的重要方法。我们旨在评估主动脉根部瘤保留瓣膜手术中再植入与重塑技术的疗效。
通过检索PubMed、Embase和Cochrane图书馆直至2019年11月进行系统评价和荟萃分析。纳入了14项比较主动脉根部瘤再植入与重塑技术的回顾性队列研究,且至少包含以下一项结局:早期死亡率、晚期死亡率、主动脉瓣相关再次手术以及术后中度至重度主动脉瓣反流(AR)。
分析了1672例患者的结局(1011例行再植入手术,661例行重塑手术)。与重塑相比,再植入技术与显著更低的晚期死亡率风险(RR =0.34;95%CI,0.17 - 0.71;P =0.004;I =37%)和再次手术风险(RR =0.31;95%CI,0.12 - 0.76;P =0.01;I =55%)相关。两组在早期死亡率(RR =0.69;95%CI,0.31 - 1.53;P =0.36;I =0%)术后中度至重度AR(RR =0.64;95%CI,0.31 - 1.32;P =0.22;I =36%)或术后卒中(RR =1.26;95%CI,0.58 - 2.75;P =0.56;I =0%)方面无显著差异。未检测到发表偏倚的证据。
当前的荟萃分析表明,接受再植入手术的患者比接受重塑手术的患者具有显著更低的晚期死亡率和再次手术风险。两种技术在早期死亡率、术后中度至重度AR和卒中方面相当。